What does LINDEPHAR do?

LINDEPHAR is a pharmacy in Evergem. Public Limited, started on 9 September 1991, 2 establishments.

What is the address of LINDEPHAR?

The registered office of LINDEPHAR is located at Lindenlaan 26, 9940 Evergem.

Is LINDEPHAR still active?

Yes. According to the CBE (29 October 2026) LINDEPHAR is active, legal situation “Normale toestand”, started on 9 September 1991.

Is LINDEPHAR registered on Peppol?

Yes, LINDEPHAR is registered on the Peppol network with ID 0208:0445084795.

What is the enterprise number of LINDEPHAR?

The enterprise number of LINDEPHAR is BE0445084795.

When was LINDEPHAR founded?

LINDEPHAR was founded on 9 September 1991.

Who are the directors of LINDEPHAR?

According to the 2025 annual accounts, the directors of LINDEPHAR are: Decura Pharma.

Is LINDEPHAR a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 September 1991; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did LINDEPHAR make in 2025?

LINDEPHAR posted a profit after taxes of € 55,567 in financial year 2025.

What is the revenue of LINDEPHAR?

As a small company, LINDEPHAR is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 592,091.

How much does an employee at LINDEPHAR earn?

The average wage cost per full-time employee at LINDEPHAR was € 70,400 in 2025: staff costs of € 394,230 for 5.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does LINDEPHAR have?

According to the 2025 annual accounts, LINDEPHAR has 5.6 full-time equivalents (FTE).

Does LINDEPHAR have a website?

Yes, LINDEPHAR has a website at feelgood.care.

LINDEPHAR (Public Limited) - Evergem - BE0445084795

Dossier LINDEPHAR, printed on 29 October 2026 from databakkes.be/en/0445084795/lindephar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 6.8 to 5.6.

Financials

Financial year 2025

LINDEPHAR from Evergem, company number BE0445084795, closed financial year 2025 with a result of € 55,567 after tax. For that financial year LINDEPHAR recorded a gross margin of € 592,091 and equity of € 791,171. Compared with financial year 2024, the result moved from € 23,327 to € 55,567. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.

What it is worth Growing

€ 791,171

▲ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 55,567

▲ 138% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 73,744

▲ 73% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 729,171.

People and assets in 2025

Full-time equivalents

5.6

▼ 0.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 394,230

▲ 2% vs 2024

€ 70,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 8,958

▼ 54% vs 2024

Of which on lease € 7,680.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 444,409

▼ 12% vs 2024

€ 89,190 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 291,557

▼ 53% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 96,651

▲ 56% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 512,550 Gross margin 2022: € 512,550 First fiscal year in the series	€ 483,255 Gross margin 2023: € 483,255 ▼ 6% vs 2022 (€ 512,550) Unfavourable step	€ 539,431 Gross margin 2024: € 539,431 ▲ 12% vs 2023 (€ 483,255) Favourable step	€ 592,091 Gross margin 2025: € 592,091 ▲ 10% vs 2024 (€ 539,431) Favourable step	▲ 10%
Profit after taxes	€ 55,369 Profit after taxes 2022: € 55,369 First fiscal year in the series	€ -9,352 Profit after taxes 2023: € -9,352 ▼ € 64,721 vs 2022 (€ 55,369) Unfavourable step	€ 23,327 Profit after taxes 2024: € 23,327 ▲ € 32,679 vs 2023 (€ -9,352) Favourable step	€ 55,567 Profit after taxes 2025: € 55,567 ▲ 138% vs 2024 (€ 23,327) Favourable step	▲ 138%
Equity	€ 721,630 Equity 2022: € 721,630 First fiscal year in the series	€ 712,277 Equity 2023: € 712,277 ▼ 1% vs 2022 (€ 721,630) Unfavourable step	€ 735,604 Equity 2024: € 735,604 ▲ 3% vs 2023 (€ 712,277) Favourable step	€ 791,171 Equity 2025: € 791,171 ▲ 8% vs 2024 (€ 735,604) Favourable step	▲ 8%
Total debts	€ 1,324,196 Total debts 2022: € 1,324,196 First fiscal year in the series	€ 1,271,236 Total debts 2023: € 1,271,236 ▼ 4% vs 2022 (€ 1,324,196) Favourable step	€ 1,195,872 Total debts 2024: € 1,195,872 ▼ 6% vs 2023 (€ 1,271,236) Favourable step	€ 839,712 Total debts 2025: € 839,712 ▼ 30% vs 2024 (€ 1,195,872) Favourable step	▼ 30%
Cash	€ 120,381 Cash 2022: € 120,381 First fiscal year in the series	€ 111,439 Cash 2023: € 111,439 ▼ 7% vs 2022 (€ 120,381) Unfavourable step	€ 42,683 Cash 2024: € 42,683 ▼ 62% vs 2023 (€ 111,439) Unfavourable step	€ 73,744 Cash 2025: € 73,744 ▲ 73% vs 2024 (€ 42,683) Favourable step	▲ 73%
Land & buildings	€ 322,918 Land & buildings 2022: € 322,918 First fiscal year in the series	€ 292,080 Land & buildings 2023: € 292,080 ▼ 10% vs 2022 (€ 322,918) Unchanged	€ 261,241 Land & buildings 2024: € 261,241 ▼ 11% vs 2023 (€ 292,080) Unchanged	€ 231,358 Land & buildings 2025: € 231,358 ▼ 11% vs 2024 (€ 261,241) Unchanged	▼ 11%
Retained profit	€ 659,630 Retained profit 2022: € 659,630 First fiscal year in the series	€ 650,277 Retained profit 2023: € 650,277 ▼ 1% vs 2022 (€ 659,630) Unfavourable step	€ 673,604 Retained profit 2024: € 673,604 ▲ 4% vs 2023 (€ 650,277) Favourable step	€ 729,171 Retained profit 2025: € 729,171 ▲ 8% vs 2024 (€ 673,604) Favourable step	▲ 8%
Bank debt	€ 633,286 Bank debt 2022: € 633,286 First fiscal year in the series	€ 578,823 Bank debt 2023: € 578,823 ▼ 9% vs 2022 (€ 633,286) Favourable step	€ 503,847 Bank debt 2024: € 503,847 ▼ 13% vs 2023 (€ 578,823) Favourable step	€ 444,409 Bank debt 2025: € 444,409 ▼ 12% vs 2024 (€ 503,847) Favourable step	▼ 12%
Balance sheet total	€ 2,045,826 Balance sheet total 2022: € 2,045,826 First fiscal year in the series	€ 1,983,513 Balance sheet total 2023: € 1,983,513 ▼ 3% vs 2022 (€ 2,045,826) Unchanged	€ 1,931,476 Balance sheet total 2024: € 1,931,476 ▼ 3% vs 2023 (€ 1,983,513) Unchanged	€ 1,630,883 Balance sheet total 2025: € 1,630,883 ▼ 16% vs 2024 (€ 1,931,476) Unchanged	▼ 16%
Employees (FTE)	6 Employees (FTE) 2022: 6 First fiscal year in the series	6.8 Employees (FTE) 2023: 6.8 ▲ 0.8 vs 2022 (6) Unchanged	6.1 Employees (FTE) 2024: 6.1 ▼ 0.7 vs 2023 (6.8) Unchanged	5.6 Employees (FTE) 2025: 5.6 ▼ 0.5 vs 2024 (6.1) Unchanged	▼ 0.5

Key figures of LINDEPHAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to LINDEPHAR?

What happened at LINDEPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 24, 2026 New annual accounts for financial year 2025: profit of € 55,567 (▲ 138% vs 2024). Source: NBB ↗
Sep 5, 2022 New establishment in Evergem. KBO
2022 Decura Pharma became a director. NBB
Jan 23, 1992 New establishment in Evergem. KBO
Sep 9, 1991 Start of the company according to the CBE. KBO

In short

From € 55,369 profit in 2022 to € 55,567 profit in 2025.

Paid € 54,874 in corporate taxes since 2022.

Best year ever: 2025, with € 55,567 profit.

On average € 105,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

DECURA PHARMA 100%

The stake of DECURA PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

LINDEPHAR

Behind LINDEPHAR is Decura Pharma. The shares are held by DECURA PHARMA (100%).

Directors

According to the 2025 annual accounts

Decura Pharma

Director · represented by Ann Raes

Also active at: MEDISALE, Deraphar, APOTHEEK RAES, FIDELMED, PHARMA FIDELMED, HEALTH AND BEAUTY SHOP, DYNA DISTRIBUTION

since 2022

Shareholders

DECURA PHARMA

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Lindenlaan 26

9940 Evergem

2.334.431.001

Pastorijstraat 70 box A

9940 Evergem

Active since 5 September 2022

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS feelgood.care

Technologies

Google FontsNginxTrustpilot

Hosting & Email

Email provider

Transip Mail

Hosting

TRANSIP-AS Amsterdam, the Netherlands, NL

DNS

TransIP DNS

Domain

feelgood.care

Registered

2015-09-04

Registrar

Key-Systems, LLC

Expires

2026-09-04

Website info

HTTPS Ja

Features

Security

✓ HTTPS

✓ SPF

✓ DMARC

Network

✓ IPv6

Details

Company number

0445.084.795

VAT number

BE 0445.084.795

Registered office

Lindenlaan 26, 9940 Evergem

Names & denominations

LINDEPHAR

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

9 September 1991

Peppol

Active · Active since 29 Aug 2023

Contact

feelgood.care

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

LINDEPHAR

Warning lights

Financials

What happened to LINDEPHAR?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Domain

Website info

Features

Security

Network

Details

Frequently asked questions